Shekhar Challa, MD
Gastroenterology · Topeka, KSNPI 1144291733
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Medtronic at 53.9% of the total. Reporting peaked in 2021 at $2,231 and has fallen 78.9% since, to $470 in 2025.
Across 138 payments — averaging $36.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AbbVie$459
- Takeda Pharmaceuticals U.S.A., Inc.$340
- Johnson & Johnson$264
- Pfizer$209
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$149
- plus $871 from 22 others
Across 1,339 payments — averaging $3281.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.4M
- Boehringer Ingelheim International GmbH$738K
- Madrigal Pharmaceuticals$473K
- GSK$451K
- Pfizer$414K
- AstraZeneca$317K
- plus $561K from 7 others
What the payments were for
- Consulting fees$60012%
- Speaking & faculty fees$2,00040%
- Food & beverage$2,37648%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 8 | $2,683 |
| AbbVie | 31 | $459 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $340 |
| Johnson & Johnson | 13 | $264 |
| Pfizer | 18 | $209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $149 |
| Echosens North America, Inc. | 2 | $129 |
| Gilead | 4 | $124 |
| Intercept Pharmaceuticals, Inc. | 8 | $121 |
| Merck | 4 | $68 |
| Madrigal Pharmaceuticals | 4 | $58 |
| Ardelyx, Inc. | 3 | $56 |
| QOL Medical, LLC | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Mauna Kea Technologies, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Sanofi | 1 | $14 |
| Amgen | 1 | $14 |
| Micro-tech Endoscopy USA, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$4,976 in reported general payments places this provider in the 75th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 18 | $1,994 |
| Pantoprazole Sodium | 211 | $1,463 |
| Dicyclomine Hcl | 15 | $201 |
| Omeprazole | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Topeka
- Curtis BaumTopeka$7K
- Balaji DattiTopeka$6K
- Richard TayTopeka$3K
- Khalil AbuamrTopeka$768
- Phani Ashok AttaluriOlathe$957K
- Ryan TaylorKansas City$241K
- Winston DunnKansas City$169K
- Francis DaileyLeawood$82K
- Rashmi TadiparthiKansas City$60K
- Prateek SharmaKansas City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.